Skip to main content

Advertisement

Table 3 Outcome measures of problem behaviors: focus on disruptive behaviors domain in fragile X syndrome

From: Updated report on tools to measure outcomes of clinical trials in fragile X syndrome

Subdomain Outcome measure Shorter term Longer term Quality of tools
Irritability/aggression
  ABC-C_I Yes Yes +++ [54, 55, 104110]
ABC-Cfx_I Yes Yes +++ [9, 46, 103, 111113]
Stereotype/self-injury/aggression BPI-S Yes   + [115117]
Variety of behaviors FXS Rating Scale Yes Yes + [63, 114]
Inattention Conners/ADHD-RS Yes   ++ [44, 64, 120, 122, 126]
Hyperactivity/impulsivity Conners/ADHD-RS Yes   ++ [44, 64, 120, 122, 126]
Hyperactivity/impulsivity/inattention CBCL_ADHD Scale Yes   ++ [130, 131]
Hyperactivity/impulsivity/inattentiona SNAP-IV Yes   ++ [40, 113, 267]
Anxiety
Social withdrawal/anxiety ABC-C_SW Yes Yes +++ [9, 19, 28, 46, 103, 111113]
Social anxiety
  PARS Yes Yes ++ [134, 138]
ADAMS Yes Yes ++ [13, 17, 113, 132, 138]
ADAMS Social Avoidance Yes Yes ++ [17, 139]
CBCL Withdrawn Yes Yes + [18, 19, 135]
CBCL’s DSM-Anxiety Yes   + [136, 137]
SCARED Yes   + [10, 13]
Repulsive/compulsive behavior RBS-R Yes   + [15, 179184]
Social reciprocity/avoidance SRS Yes Yes +/++ [15, 46, 7881, 112, 113]
  1. Abbreviations: ABC-C Aberrant Behavior Checklist-Community Edition, ABC-C_I ABC-C, Irritability subscale, ABC-C FX_ I ABC-C, FXS-specific, Irritability subscale, BPI Behavior Problems Inventory, ADHD-RS Attention-Deficit Hyperactivity Rating Scale, CBCL_ADHD Scale Child Behavior Checklist_ADHD subscale, SNAP-IV Swanson, Nolan and Pelham Questionnaire-4th ed. ABC-C_SW ABC-C, Lethargy/Social Withdrawal subscale, PARS Pediatric Anxiety Rating Scale, ADAMS Anxiety Depression and Mood Scale, CBCL Withdrawn CBCL Withdrawn Subscale, CBCL’s DSM-Anxiety CBCL’s Diagnostic and Statistical Manual-Anxiety Subscale, SCARED Screen For Child Anxiety Related Emotional Disorders, RBS-R Repetitive Behavior Scale-Revised, SRS Social Responsive Scale, shorter term deemed suitable for clinical trials lasting <12 months; longer term deemed suitable for clinical trials lasting >=12 months. Grading system: +++ strong, ++ moderate, + limited evidence, ? unknown/poor methodological quality, blank cell no evidence available
  2. aOppositional and defiant items are also included